FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100828255> ?p ?o ?g. }

• W3100828255 abstract "Background: The 2017 AHA/ACC/HFSA Focused Update of the 2013 ACC/AHA Guidelines for the Management of Heart Failure provided additional support for the clinical use of ACEI, ARBs or ARNIs in conjunction with Evidence-Based Beta Blockers and Aldosterone Antagonists in HFrEF, otherwise known as Guideline-Directed Medical Therapy (GDMT). Although these updates clarified the benefits of GDMT to patient outcomes, low rates of adherence at the provider level for both hospitalized and ambulatory patients continue to be seen. Methods: With the objective of rapidly improving GDMT utilization, as well as improving patient outcomes, the American Heart Association initiated a multidisciplinary collaborative in three metropolitan markets - Chicago, Milwaukee, and St. Louis. Utilizing Get With The Guidelines®-Heart Failure (GWTG-HF), 40 hospitals tracked patients discharged with a primary diagnosis of heart failure and entered data from their inpatient and 30-days post-acute record. An initiative benchmark group was created to track progress and revisions were made to the post-acute care form. Hospitals were provided targeted consultation using hospital-specific data compared to regional and initiative benchmarks. The initiative provided exclusive professional education, including webinars, collaboration meetings, and best-practice recommendations. Results: Between January 1, 2019 and December 31, 2019, 10,532 patients with a primary diagnosis of heart failure, were entered into GWTG-HF from the 40 initiative hospitals, in which 3807 had an EF of <40%. A comparison from Q1 to Q4, 2019 of the mean adherence for GDMT was performed at discharge and yielded the following results: ACEI/ARB or ARNi from 89.3% to 91.6%, Evidenced-Based Beta Blockers from 90.3% to 94.2% and Aldosterone Antagonist from 53.6% to 64.7%; At 30-Days the mean adherence for Q1 and Q4 were calculated as follows: ACEI/ARB or ARNi from 60.4% to 72.9% and Aldosterone Antagonist from 28.2% to 55.3%. Evidence-Based Beta Blocker was only captured for Q3 and Q4, 2019 and the mean adherence improved from 70.3% to 73.8%. Conclusions: The multi-city quality initiative early results show a positive correlation in improving adherence to GDMT in both the hospital and ambulatory setting." @default.
• W3100828255 created "2020-11-23" @default.
• W3100828255 creator A5029553453 @default.
• W3100828255 creator A5033676135 @default.
• W3100828255 creator A5046247676 @default.
• W3100828255 creator A5053502923 @default.
• W3100828255 creator A5055502035 @default.
• W3100828255 creator A5072753901 @default.
• W3100828255 creator A5075739287 @default.
• W3100828255 creator A5077648198 @default.
• W3100828255 date "2020-11-17" @default.
• W3100828255 modified "2023-10-18" @default.
• W3100828255 title "Abstract 14370: Rapidly Improving Adherence to Guideline-Directed Medical Therapies in Metropolitan Heart Failure Systems of Care" @default.
• W3100828255 doi "https://doi.org/10.1161/circ.142.suppl_3.14370" @default.
• W3100828255 hasPublicationYear "2020" @default.
• W3100828255 type Work @default.
• W3100828255 sameAs 3100828255 @default.
• W3100828255 citedByCount "0" @default.
• W3100828255 crossrefType "journal-article" @default.
• W3100828255 hasAuthorship W3100828255A5029553453 @default.
• W3100828255 hasAuthorship W3100828255A5033676135 @default.
• W3100828255 hasAuthorship W3100828255A5046247676 @default.
• W3100828255 hasAuthorship W3100828255A5053502923 @default.
• W3100828255 hasAuthorship W3100828255A5055502035 @default.
• W3100828255 hasAuthorship W3100828255A5072753901 @default.
• W3100828255 hasAuthorship W3100828255A5075739287 @default.
• W3100828255 hasAuthorship W3100828255A5077648198 @default.
• W3100828255 hasConcept C126322002 @default.
• W3100828255 hasConcept C142724271 @default.
• W3100828255 hasConcept C158739034 @default.
• W3100828255 hasConcept C177713679 @default.
• W3100828255 hasConcept C194828623 @default.
• W3100828255 hasConcept C2778198053 @default.
• W3100828255 hasConcept C2780182762 @default.
• W3100828255 hasConcept C35785553 @default.
• W3100828255 hasConcept C545542383 @default.
• W3100828255 hasConcept C71924100 @default.
• W3100828255 hasConceptScore W3100828255C126322002 @default.
• W3100828255 hasConceptScore W3100828255C142724271 @default.
• W3100828255 hasConceptScore W3100828255C158739034 @default.
• W3100828255 hasConceptScore W3100828255C177713679 @default.
• W3100828255 hasConceptScore W3100828255C194828623 @default.
• W3100828255 hasConceptScore W3100828255C2778198053 @default.
• W3100828255 hasConceptScore W3100828255C2780182762 @default.
• W3100828255 hasConceptScore W3100828255C35785553 @default.
• W3100828255 hasConceptScore W3100828255C545542383 @default.
• W3100828255 hasConceptScore W3100828255C71924100 @default.
• W3100828255 hasIssue "Suppl_3" @default.
• W3100828255 hasLocation W31008282551 @default.
• W3100828255 hasOpenAccess W3100828255 @default.
• W3100828255 hasPrimaryLocation W31008282551 @default.
• W3100828255 hasRelatedWork W2025193597 @default.
• W3100828255 hasRelatedWork W2093331292 @default.
• W3100828255 hasRelatedWork W2116837763 @default.
• W3100828255 hasRelatedWork W2149046625 @default.
• W3100828255 hasRelatedWork W2401929541 @default.
• W3100828255 hasRelatedWork W2419095768 @default.
• W3100828255 hasRelatedWork W3108214080 @default.
• W3100828255 hasRelatedWork W320511385 @default.
• W3100828255 hasRelatedWork W4310107700 @default.
• W3100828255 hasRelatedWork W118488404 @default.
• W3100828255 hasVolume "142" @default.
• W3100828255 isParatext "false" @default.
• W3100828255 isRetracted "false" @default.
• W3100828255 magId "3100828255" @default.
• W3100828255 workType "article" @default.